Compounds > 4-phosphoerythronate
Page last updated: 2024-12-08

4-phosphoerythronate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-phosphoerythronate: inhibits ribose-5-phosphate isomerase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-phospho-D-erythronic acid : The D-enantiomer of 4-phosphoerythronic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID449304
CHEMBL ID1160945
CHEBI ID49003
SCHEMBL ID420471
MeSH IDM0074204

Synonyms (18)

Synonym
(2r,3r)-2,3-dihydroxy-4-(phosphonooxy)butanoic acid
CHEBI:49003 ,
4-o-phosphono-d-erythronic acid
4-phosphoerythronate
C03393
4-phospho-d-erythronate
2BET
DB03108
4-phospho-d-erythronic acid
(2r,3r)-2,3-dihydroxy-4-phosphonooxybutanoic acid
[r-(r*,r*)]-2,3-dihydroxy-4-(phosphonooxy)butanoic acid
4-phospho d-erythronate
CHEMBL1160945
57229-25-1
SCHEMBL420471
DTXSID70332305
Q27104642
PD059855

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" A virtual fragment screen was undertaken of the enzyme to discover starting points for the development of inhibitors which are likely to have appropriate physicochemical properties for an orally bioavailable compound."( Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
Alibu, VP; Barrett, MP; Brenk, R; Campbell, G; Gilbert, IH; Ruda, GF, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
4-phosphoerythronic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Superpathway of pyridoxal 5'-phosphate biosynthesis and salvage014
Pyridoxal 5'-phosphate biosynthesis020

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
6-phosphogluconate dehydrogenase, decarboxylatingOvis aries (sheep)Ki10.79002.54002.54002.5400AID492275
6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)Ki5.41500.01002.74508.3000AID7236; AID7238
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
pentose-phosphate shunt6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose-phosphate shunt, oxidative branch6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose biosynthetic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
D-gluconate catabolic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
phosphogluconate dehydrogenase (decarboxylating) activity6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
NADP binding6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleus6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
extracellular exosome6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID492273Inhibition of Trypanosoma brucei 6PGDH expressed in Escherichia coli by spectroscopy2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID492275Inhibition of sheep 6PGDH expressed in Escherichia coli by spectroscopy2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
AID594840Inhibition of Escherichia coli arabinose phosphate isomerase2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.
AID7236Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID229393Selectivity ratio of inhibition constant of compound against 6-phosphogluconate dehydrogenase of sheep to 6-phosphogluconate dehydrogenase of Trypanosoma brucei2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
AID7238Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's3 (27.27)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phosphoglycolate
phosphoglycolate: RN given refers to parent acid. 2-phosphoglycolic acid : The O-phospho derivative of glycolic acid.		2.1310carboxyalkyl phosphateEscherichia coli metabolite;
mouse metabolite
fosmidomycin
fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source. fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.		2.2110hydroxamic acid;
phosphonic acids		antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor
pyridoxal phosphate
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).. pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.		1.9810methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
phosphoglycolohydroxamate
phosphoglycolohydroxamate: inhibits DHAP (dihydroxyacetone phosphate)-converting enzymes; structure. phosphoglycolohydroxamic acid : The hydroxamate of phosphoglycolic acid.		2.0610amidoalkyl phosphate;
hydroxamic acid		EC 5.3.1.1 (triose-phosphate isomerase) inhibitor
phenylmethanesulfonic acid
phenylmethanesulfonic acid: RN given refers to parent cpd		2.0510
copper gluconate
Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.		2.4720organic molecular entity
cysteic acid
Cysteic Acid: Beta-Sulfoalanine. An amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather.. cysteic acid : An amino sulfonic acid that is the sulfonic acid analogue of cysteine.		2.0510alanine derivative;
amino sulfonic acid;
carboxyalkanesulfonic acid;
cysteine derivative;
non-proteinogenic alpha-amino acid		animal metabolite
6-phosphogluconic acid
gluconic acid-6-phosphate: structure. 6-phospho-D-gluconate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of 6-phospho-D-gluconic acid.. 6-phospho-D-gluconic acid : A gluconic acid phosphate having the phosphate group at the 6-position. It is an intermediate in the pentose phosphate pathway.		2.4720gluconic acid phosphatefundamental metabolite
fructose 2,6-diphosphate
fructose 2,6-diphosphate: phosphofructokinase activator synthesized via Mg-ATP & fructose-6-P. beta-D-fructofuranose 2,6-bisphosphate : A D-fructofuranose 2,6-bisphosphate with a beta-configuration at the anomeric centre.		2.1310D-fructofuranose 2,6-bisphosphatehuman metabolite;
mouse metabolite
glyceraldehyde 3-phosphate dehydrogenase (304-313)
glyceraldehyde 3-phosphate dehydrogenase (304-313): from Bacillus stearothermophilus		1.9810
erythrose 4-phosphate
erythrose 4-phosphate: RN given refers to (R-(R*,R*))-isomer. D-erythrose 4-phosphate : An erythrose phosphate that is D-erythrose carrying a phosphate group at position 4. It is an intermediate in the pentose phosphate pathway and Calvin cycle.		1.9810erythrose phosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite
2-phospholactic acid
2-phospholactic acid: RN given refers to cpd without isomeric designation. 2-phospholactic acid : The phosphoric acid monoester resulting from formal condensation of the alcohol group of lactic acid with phosphoric acid.		2.8430carboxyalkyl phosphate
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		2.2110epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
4-phospho-d-erythronohydroxamic acid
[no description available]		2.7330
Thieno[3,2-b]thiophene-2-carboxylic acid
[no description available]		2.0510thienothiophene
nadp
[no description available]		2.0310
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9810organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
African Sleeping Sickness
[description not available]		02.0510
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		02.0510
Plasmodium falciparum Malaria
[description not available]		02.2110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.2110